



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

March 3, 2020

Via E-mail

Kim C. Drapkin  
Chief Financial Officer  
Jounce Therapeutics, Inc.  
780 Memorial Drive  
Cambridge, MA 02139

**Re: Jounce Therapeutics, Inc.  
Form 10-Q for the Quarterly Period Ended September 30, 2019  
Exhibit No. 10.1 - License Agreement by and among the Registrant, Celgene Corporation, and Celgene RIVOT LLC, dated July 22, 2019  
Filed November 7, 2019  
File No. 001-37998**

Dear Ms. Drapkin:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance